Inhibrx INBX Stock
Inhibrx Price Chart
Inhibrx INBX Financial and Trading Overview
| Inhibrx stock price | 34.15 USD |
| Previous Close | 26.89 USD |
| Open | 26.82 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 1400 |
| Day's Range | 26.49 - 28.7 USD |
| 52 Week Range | 8.62 - 34.72 USD |
| Volume | 319.57K USD |
| Avg. Volume | 374.49K USD |
| Market Cap | 1.21B USD |
| Beta (5Y Monthly) | 2.857898 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49 USD |
INBX Valuation Measures
| Enterprise Value | 1.15B USD |
| Trailing P/E | N/A |
| Forward P/E | -6.4999995 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 947.96 |
| Price/Book (mrq) | 80.17291 |
| Enterprise Value/Revenue | 895.643 |
| Enterprise Value/EBITDA | -8.036 |
Trading Information
Inhibrx Stock Price History
| Beta (5Y Monthly) | 2.857898 |
| 52-Week Change | 206.38% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 34.72 USD |
| 52 Week Low | 8.62 USD |
| 50-Day Moving Average | 23.01 USD |
| 200-Day Moving Average | 24.19 USD |
INBX Share Statistics
| Avg. Volume (3 month) | 374.49K USD |
| Avg. Daily Volume (10-Days) | 353.99K USD |
| Shares Outstanding | 43.62M |
| Float | 17.92M |
| Short Ratio | 13.9 |
| % Held by Insiders | 21.62% |
| % Held by Institutions | 83.79% |
| Shares Short | 5.95M |
| Short % of Float | 21.46% |
| Short % of Shares Outstanding | 13.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -11239.53% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -43.34% |
| Return on Equity (ttm) | -766.83% |
Income Statement
| Revenue (ttm) | 1.28M USD |
| Revenue Per Share (ttm) | 0.03 USD |
| Quarterly Revenue Growth (yoy) | -98.20% |
| Gross Profit (ttm) | -107994000 USD |
| EBITDA | -142652992 USD |
| Net Income Avi to Common (ttm) | -162888000 USD |
| Diluted EPS (ttm) | -4.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 234.25M USD |
| Total Cash Per Share (mrq) | 5.37 USD |
| Total Debt (mrq) | 207.85M USD |
| Total Debt/Equity (mrq) | 1373.5 USD |
| Current Ratio (mrq) | 7.469 |
| Book Value Per Share (mrq) | 0.347 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -128304000 USD |
| Levered Free Cash Flow (ttm) | -69121872 USD |
Profile of Inhibrx
| Country | United States |
| State | CA |
| City | La Jolla |
| Address | 11025 North Torrey Pines Road |
| ZIP | 92037 |
| Phone | 858 795 4220 |
| Website | https://inhibrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 132 |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.
Q&A For Inhibrx Stock
What is a current INBX stock price?
Inhibrx INBX stock price today per share is 34.15 USD.
How to purchase Inhibrx stock?
You can buy INBX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inhibrx?
The stock symbol or ticker of Inhibrx is INBX.
Which industry does the Inhibrx company belong to?
The Inhibrx industry is Biotechnology.
How many shares does Inhibrx have in circulation?
The max supply of Inhibrx shares is 48.55M.
What is Inhibrx Price to Earnings Ratio (PE Ratio)?
Inhibrx PE Ratio is now.
What was Inhibrx earnings per share over the trailing 12 months (TTM)?
Inhibrx EPS is -5.12 USD over the trailing 12 months.
Which sector does the Inhibrx company belong to?
The Inhibrx sector is Healthcare.
Inhibrx INBX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}